A ortic stenosis is an insidious disease with a long latency period 1 followed by rapid progression after the appearance of symptoms, 2-5 resulting in a high rate of death (approximately 50% in the first 2 years after symptoms appear) among untreated patients. 1, [6] [7] [8] Surgical replacement of the aortic valve reduces symptoms and improves survival in patients with aortic stenosis, [9] [10] [11] and in the absence of serious coexisting conditions, the procedure is associated with low operative mortality. 12, 13 However, in clinical practice, at least 30% of patients with severe symptomatic aortic stenosis do not undergo surgery for replacement of the aortic valve, owing to advanced age, left ventricular dysfunction, or the presence of multiple coexisting conditions. [14] [15] [16] [17] For these patients, who are at high surgical risk, 18, 19 a less invasive treatment may be a worthwhile alternative.
Transcatheter aortic-valve implantation (TAVI) is a new procedure, in which a bioprosthetic valve is inserted through a catheter and implanted within the diseased native aortic valve. Since 2002, when the procedure was first performed, 20, 21 there has been rapid growth in its use throughout the world for the treatment of severe aortic stenosis in patients who are at high surgical risk. [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] The most recent clinical studies showed that the rate of death from any cause at 1 year among patients treated with TAVI was approximately 25%. [27] [28] [29] 31 Thus far, all the studies of TAVI have been observational registry studies, without standardization of end-point definitions 33, 34 (and unpublished data) and without control populations. There is a paucity of rigorous, evidence-based clinical data to substantiate the incremental benefits of TAVI as compared with current standard therapies.
The Placement of Aortic Transcatheter Valves (PARTNER) trial was a multicenter, randomized clinical trial comparing TAVI with standard therapy in high-risk patients with severe aortic stenosis, including a prespecified cohort of patients who were not considered to be suitable candidates for surgery. In this article, we report the outcomes with TAVI as compared with standard therapy among the patients in the PARTNER trial who were not suitable candidates for surgery.
Me thods

Patient Selection
We enrolled in the PARTNER trial patients with severe aortic stenosis and cardiac symptoms for whom conventional surgery to replace the aortic valve was associated with high risk. Severe aortic stenosis was defined as an aortic-valve area of less than 0.8 cm 2 , a mean aortic-valve gradient of 40 mm Hg or more, or a peak aortic-jet velocity of 4.0 m per second or more. All the patients had New York Heart Association (NYHA) class II, III, or IV symptoms. Patients were divided into two cohorts: those who were considered to be candidates for surgery despite the fact that they were at high surgical risk, as defined by a Society of Thoracic Surgeons (STS) risk score of 10% or higher 35 (on a scale of 0% to 100%, with higher scores indicating greater surgical risk) or by the presence of coexisting conditions that would be associated with a predicted risk of death by 30 days after surgery of 15% or higher, and those who were not considered to be suitable candidates for surgery because they had coexisting conditions that would be associated with a predicted probability of 50% or more of either death by 30 days after surgery or a serious irreversible condition. At least two surgeon investigators had to agree that the patient was not a suitable candidate for surgery. In this article, we report the results for the patients with aortic stenosis who were not considered to be suitable candidates for surgery. The randomized trial involving patients at high surgical risk who were nevertheless considered to be candidates for surgery (also NCT00530894) is ongoing.
Pertinent exclusion criteria were a bicuspid or noncalcified aortic valve, acute myocardial infarction, substantial coronary artery disease requiring revascularization, a left ventricular ejection fraction of less than 20%, a diameter of the aortic annulus of less than 18 mm or more than 25 mm, severe (>3+) mitral or aortic regurgitation, a transient ischemic attack or stroke within the previous 6 months, and severe renal insufficiency. The complete list of inclusion and exclusion criteria is provided in Table 1 in the Supplementary Appendix, available with the full text of this article at NEJM.org.
After investigators screened the patients for eligibility, Web-based conference calls were conducted by the executive committee to further review and approve the selection of all patients before randomization. Of the 3105 patients with aortic stenosis who were screened by the investigators and the executive committee, approximately 12% ultimately underwent randomization as part of the PARTNER trial and were assigned to the cohort of patients who were not considered to be suitable candidates for surgery.
Study Device and Procedure
The Edwards SAPIEN heart-valve system (Edwards Lifesciences) consists of a trileaflet bovine pericardial valve and a balloon-expandable, stainlesssteel support frame. The heart valve is shown in Figure 1 in the Supplementary Appendix. The TAVI procedure was performed in a sterile environment (catheterization laboratory or operating room), with the patient under general anesthesia; the procedure was performed with the use of transesophageal echocardiography. A standard balloon aortic valvuloplasty was performed, followed by transfemoral insertion of either a 22-or 24-French sheath, depending on the selected size of the valve (23 mm or 26 mm). The bioprosthetic heart valve, crimped onto a balloon catheter, was advanced across the native aortic valve. During rapid right ventricular pacing, balloon inflation of the crimped heart valve and support frame simultaneously deployed the bioprosthetic valve and expanded the frame, which was secured to the underlying aortic-valve annulus and leaflets (see videos 1 and 2, available at NEJM.org). Adjunctive pharmacologic therapy included heparin during the procedure and dual antiplatelet therapy (aspirin and clopidogrel) for 6 months after the procedure.
Study Design and Oversight
The PARTNER study incorporated two parallel prospective, multicenter, randomized, active-treatment-controlled clinical trials. The overall study design is shown in Figure 2 in the Supplementary Appendix. Patients were randomly assigned with the use of a computer-generated scheme, blocked separately at each participating site and for each of the trial cohorts. The PARTNER study was approved by the institutional review board at each participating site, and all patients provided written informed consent. The trial was designed by the sponsor (Edwards Lifesciences) and members of the executive committee, which included the two academic coprincipal investigators, three interventional cardiologists, and three cardiac surgeons. The sponsor funded the studies and participated in the selection and management of the sites and the collection and monitoring of the data. The executive committee met in person every 6 to 8 weeks to monitor all aspects of the conduct of the trial. The coprincipal investigators and the executive committee had unrestricted access to the data after the database was locked, made the decision to submit the manuscript for publication, prepared all drafts of the manuscript, and attest to the integrity of the trial and the completeness and accuracy of the reported data, as well as to the fidelity of the report to the trial protocol. The protocol, including the statistical analysis plan, is available at NEJM.org.
Data Management
All serious adverse events were adjudicated by an independent clinical events committee. A data and safety monitoring board met frequently and had access to all study data and treatment assignments when requested; the board recommended after each meeting that the study be continued without modification. All data were sent for analysis to independent consulting biostatisticians. Independent core laboratories analyzed all echocardiograms and electrocardiograms. The members of the committees, the institutions, and the research organizations participating in the PARTNER trial are listed in Table 2 in the Supplementary Appendix.
Study End Points
The primary end point was the rate of death from any cause over the duration of the trial. All patients were followed for at least 1 year, and crossover from the standard-therapy group to the TAVI group was not permitted. The coprimary end point was the rate of a hierarchical composite of the time to death from any cause or the time to the first occurrence of repeat hospitalization (after the index procedure) due to valve-related or procedurerelated clinical deterioration. This composite end point was also reported with the use of more conventional Kaplan-Meier nonhierarchical analytical methods. Prespecified secondary end points included the rate of death from cardiovascular causes, NYHA functional class, the rate of repeat hospitalization due to valve-related or procedurerelated clinical deterioration, the distance covered during a 6-minute walk test, 36 valve performance (assessed by echocardiography), and the rates of myocardial infarction, stroke, acute kidney injury, vascular complications, and bleeding. A major stroke was defined as a focal or global neurologic deficit associated with a score of 2 or higher on the modified Rankin scale, which has a range of 0 to 6, with 0 indicating no symptoms and 6 in- portant end points are provided in Table 3 in the Supplementary Appendix. All patients were followed during the index hospitalization; at 30 days, 6 months, and 1 year; and yearly thereafter.
Statistical Analysis
We estimated that with a sample of 350 patients, the study would have at least 85% power to show the superiority of TAVI over standard treatment with respect to the primary end point, assuming that 1-year mortality would be 37.5% in the standard-treatment group and 25% in the TAVI group.
In calculating the size of the sample, we also assumed that deaths would follow a constant hazard distribution, that follow-up would continue for 12 months after the last patient was enrolled, and that the rate of loss to follow-up would be 10%. The analysis of the coprimary end point -the hierarchical composite of death or repeat hospitalization -was performed with the use of a nonparametric method described by Finkelstein and Schoenfeld. 37 With this method, multiple pairwise comparisons are performed for all patient pairs, first with respect to the time to death and then with respect to the time to repeat hospitalization, if necessary. On the basis of a simulation with the use of SAS software, we estimated that with a total sample of 350 patients, the power for this coprimary end point would be more than 95%. The Hochberg procedure was used to make multiple corrections of the primary and coprimary end points.
Categorical variables were compared with the use of Fisher's exact test. A generalized linear model was used to calculate risk ratios in the subgroup analysis and to test for interactions. Continuous variables, which are presented as means (±SD), were compared with the use of Student's t-test. All the analyses were performed with data from the intention-to-treat population, which included all patients who underwent randomization, regardless of the treatment actually received. Survival curves for time-to-event variables were constructed on the basis of all available followup data with the use of Kaplan-Meier estimates and were compared with the use of the log-rank test. A two-sided alpha level of 0.05 was used for all superiority testing. All statistical analyses were performed with the use of SAS software, version 9.2.
R e sult s
Patients and Enrollment
Between May 11, 2007 , and March 16, 2009, a total of 358 patients with severe aortic stenosis who were not suitable candidates for surgery were enrolled at 21 sites (17 in the United States) and were randomly assigned to TAVI (179 patients) or standard therapy (179 patients). All the patients were followed for at least 1 year (median follow-up period, 1.6 years; maximum, 2.8 years). The numbers of patients who underwent randomization and follow-up are shown in Figure 3 in the Supplementary Appendix.
The baseline characteristics of the patients in the two groups were generally well balanced (Table 1). The overall patient population was at high risk (STS score, 11.6±6.0%). However, there were many patients with low STS scores but with coexisting conditions that contributed to the surgeons' determination that the patient was not a suitable candidate for surgery, including an extensively calcified (porcelain) aorta (15.1%), chestwall deformity or deleterious effects of chest-wall irradiation (13.1%), oxygen-dependent respiratory insufficiency (23.5%), and frailty, as determined by the surgeons according to prespecified criteria (23.1%).
Procedural Outcomes
Of the 179 patients assigned to TAVI, 6 (3.4%) did not receive a transcatheter heart valve (2 patients died before the scheduled implantation, transfemoral access was unsuccessful in 2 patients, and the intraprocedural annulus measurement was too large in 2 patients). After randomization, the median time to TAVI was 6 days (interquartile range, 3 to 11). During the TAVI procedure or in the first 24 hours after the procedure, 2 patients (1.1%) died, 3 (1.7%) had major strokes, 1 (0.6%) had a valve embolization, and 2 (1.1%) underwent multiple (≥2) valve implantations; no patient underwent urgent cardiac surgery to manage complications. In the first 30 days after the procedure, 11 of the 173 patients who underwent TAVI (6.4%) died.
Of the 179 patients assigned to standard therapy, balloon aortic valvuloplasty was performed in 114 patients (63.7%) during the 30 days after randomization and in an additional 36 patients (20.1%) more than 30 days after randomization. Despite the fact that all the patients in this cohort of the PARTNER study were determined not to be suitable candidates for surgery, 12 of the patients who were assigned to standard therapy (6.7%) underwent aortic-valve replacement, 5 (2.8%) underwent placement of a conduit from the left ventricular apex to the descending aorta plus aorticvalve replacement, and 4 (2.2%) underwent TAVI at a nonparticipating site outside the United States.
The 1-year rates of death among patients in the standard-therapy group who underwent aorticvalve replacement, conduit plus aortic-valve replacement, or TAVI at a nonparticipating site outside the United States were 33%, 80%, and 0%, respectively.
Rates of Death, Repeat Hospitalization, and Stroke
At 30 days after randomization, the rate of death from any cause was 5.0% in the TAVI group as compared with 2.8% in the standard-therapy group (P = 0.41) ( (Fig. 1A) . The rate of death from cardiovascular causes at 1 year (Kaplan-Meier analysis) was also lower in the TAVI group than in the standard-therapy group (20.5% vs. 44.6%; hazard ratio, 0.39; 95% CI, 0.27 to 0.56; P<0.001) (Fig. 1B) . The specific cardiovascular and noncardiovascular causes of death are shown in Table 4 in the Supplementary Appendix. The superiority of TAVI with respect to the coprimary end point (the rate of the hierarchical composite of death from any cause or repeat hospitalization) was confirmed by the FinkelsteinSchoenfeld analysis (P<0.001). In addition, the rate of the nonhierarchical composite of death from any cause or repeat hospitalization at the 1-year follow-up (Kaplan-Meier analysis) was 42.5% with TAVI as compared with 71.6% with standard therapy (hazard ratio, 0.46; 95% CI, 0.35 to 0.59; P<0.001) (Fig. 1C) .
Major strokes were observed more frequently in the TAVI group than in the standard-therapy group at 30 days (5.0% vs. 1.1%, P = 0.06) and at 1 year (7.8% vs. 3.9%, P = 0.18). However, the rate of the composite of major stroke or death from any cause (Kaplan-Meier analysis) was still significantly lower in the TAVI group than in the standard-therapy group (33.0% vs. 51.3% at 1 year; hazard ratio, 0.58; 95% CI, 0.43 to 0.78; P<0.001) (Fig. 1D) . A more detailed analysis of the neurologic events is shown in Table 5 in the Supplementary Appendix.
Subgroup analyses with interaction testing were performed to determine whether the reduction in the primary end point (the rate of death from any cause) after TAVI was consistent across 10 important subgroups (Fig. 2) . No significant interactions were observed.
Other Clinical Outcomes
The frequencies of other important clinical events at 30 days and at 1 year are shown in Table 2 . Major vascular complications and major bleeding events were more frequent in the TAVI group than in the standard-therapy group. At 30 days, 6 months, and 1 year, symptoms were significantly reduced in the TAVI group (P<0.001 for all three comparisons) (Fig. 3) . At 1 year, 74.8% of the surviving patients who had undergone TAVI, as compared with 42.0% of the surviving patients who had received standard therapy, were asymptomatic or had mild symptoms (NYHA class I or II) (P<0.001). The 6-minute walk test could be performed in only a subgroup of patients, owing to the presence of coexisting conditions in many of the patients. At 1 year, a paired analysis of the distance covered during a 6-minute walk test showed that there was significant improvement after TAVI (P = 0.002) and no change after standard therapy (P = 0.67).
Echocardiographic Findings
Echocardiographic findings are shown in Table 6 in the Supplementary Appendix. Among patients who underwent TAVI, the mean aortic-valve area increased from 0.6±0.2 cm 2 at baseline to 1.5±0.5 cm 2 at 30 days (P<0.001), and the mean aorticvalve gradient decreased from 44.5±15.7 mm Hg to 11.1±6.9 mm Hg (P<0.001). At the 1 year follow-up assessment, the improvement in aorticvalve area and mean gradient was maintained.
Moderate or severe paravalvular aortic regurgitation was present in 11.8% of the patients in the TAVI group at 30 days and in 10.5% at 1 year. There were no substantial changes (i.e., changes of more than one grade) in paravalvular aortic regurgitation in the TAVI group during the 1-year follow-up period. The incidence of moderate or severe transvalvular aortic regurgitation was 1.3%
The † P values are for between-group comparisons of the frequency of the event at each time point. ‡ Deaths from unknown causes were assumed to be deaths from cardiovascular causes. § Repeat hospitalizations were included if they were due to aortic stenosis or complications of the valve procedure (e.g., TAVI). ¶ Patients who received renal-replacement therapy were not included. ‖ Patients who received renal-replacement therapy after randomization were included. ** One patient in the TAVI group did not receive TAVI (because of failed access) and subsequently underwent balloon aortic valvuloplasty, followed by aortic-valve replacement. † † A total of 30 patients underwent a repeat balloon aortic valvuloplasty after the index balloon aortic valvuloplasty procedure that had been performed in the first 30 days after randomization, and 36 patients underwent a first balloon aortic valvuloplasty more than 30 days after randomization. ‡ ‡ Three patients underwent a repeat TAVI within 24 hours after the index TAVI procedure; four patients in the standard-therapy group who underwent TAVI at a nonparticipating site outside the United States are not included here.
The at 30 days and 4.2% at 1 year among patients in the TAVI group, as compared with 16.9% and 15.2%, respectively, among patients in the standard-therapy group. Three patients in the TAVI group (1.7%) had to undergo an additional procedure (repeat TAVI) to treat clinically significant aortic regurgitation (paravalvular in two patients and transvalvular in one).
Discussion
The main results from the PARTNER trial in the cohort of patients with aortic stenosis who were not suitable candidates for surgery can be summarized as follows. First, standard medical therapy (including balloon aortic valvuloplasty, which was performed in 83.8% of the patients in the standard-therapy group) did not alter the natural history of severe aortic stenosis; at the end of 1 year, the rate of death from any cause was 50.7%, and the rate of death from cardiovascular causes was 44.6%. Second, transfemoral TAVI was superior to standard therapy, markedly reducing the rate of death from any cause (the primary end point), the rate of death from cardiovascular causes, and the rate of repeat hospitalization. In the first year, only five patients needed to be treated with TAVI to prevent one death, and only three patients needed to be treated to prevent either a death or repeat hospitalization. Third, the rate of death at 30 days among patients who underwent TAVI (5.0% in the intention-to-treat population, and 6.4% among patients who underwent TAVI) did not differ significantly from that among patients who received standard therapy in this cohort of patients who were not suitable candidates for surgery, despite the use of early-generation systems for TAVI and minimal operator experience with the TAVI procedure before the trial was initiated. Fourth, TAVI was also associated with a significant reduction in symptoms, as assessed with the use of the NYHA classification system and the results of a 6-minute walk test. Fifth, there were more neurologic events (including all strokes and major strokes), major vascular complications, and major bleeding events in the TAVI group than in the standard-therapy group. Sixth, echocardiographic findings after TAVI indicated that the hemodynamic performance of the bioprosthetic valve was excellent and that there was no evidence of deterioration in the first year. TAVI was accompanied by the frequent occurrence of paravalvular regurgitation, which was usually mild, remained stable during the 1-year follow-up period, and rarely required further treatment for worsening symptoms.
The early clinical outcomes (at ≤30 days) after transfemoral TAVI were similar to those seen in other recent studies of the same balloon-expandable bovine pericardial heart valve. 28, 29, 31, 32 Relative risks and 95% confidence intervals are shown for the primary end point of death from any cause at 1 year among patients randomly assigned to transcatheter aortic-valve implantation (TAVI) or standard therapy. The P value for interaction represents the likelihood of an interaction between the variable and the relative treatment effect. The body-mass index is the weight in kilograms divided by the square of the height in meters. The Society of Thoracic Surgeons (STS) score measures patient risk at the time of cardiovascular surgery on a scale that ranges from 0% to 100%, with higher scores indicating greater risk. Moderate or severe mitral regurgitation was defined as regurgitation of grade 3+ or higher. CABG denotes coronary-artery bypass grafting, COPD chronic obstructive pulmonary disease, LV left ventricular, NNT number needed to treat, and PCI percutaneous coronary intervention.
The doubtedly, the large femoral access sheaths that are required to insert this TAVI system contributed to the frequent occurrence of vascular complications and bleeding events. Ongoing studies are assessing the use of a lower-profile valve and support frame, which may reduce vascular complications, allow patients who have smaller iliofemoral arteries than did patients in this study to undergo this procedure, and facilitate percutaneous access and closure. Strokes remain a troublesome adverse effect following TAVI; strokes occur more frequently among patients who undergo TAVI than among patients who receive standard therapy. Recently, diffusion-weighted magnetic resonance imaging studies have shown that there are new perfusion deficits in many patients after TAVI, presumably due to atherothrombotic emboli. 38, 39 The combination of smaller, less traumatic TAVI systems than the ones currently in use and novel cerebral protection devices is being evaluated in an effort to reduce the frequency of embolic neurologic events associated with TAVI. Additional randomized clinical trials are needed to compare the frequency of procedural strokes after TAVI with the frequency after surgical aorticvalve replacement.
Our study has several limitations. The protocolmandated selection criteria excluded important patient subgroups, such as patients requiring treatment of coronary stenoses and patients with severe peripheral vascular disease. An assessment of the durability and the long-term clinical safety and effectiveness of the bioprosthetic valves will require more prolonged follow-up of patients who participated in the PARTNER trial and in other clinical trials of TAVI. Because TAVI was a relatively new procedure in the United States at the time the PARTNER trial was conducted, there was still a learning curve for most of the surgeons and interventional cardiologists who performed TAVI in the United States, and this relative inexperience was compounded by the use of an earliergeneration delivery system that was more likely to cause complications.
On the basis of a rate of death from any cause at 1 year that was 20 percentage points lower with TAVI than with standard therapy, balloon-expandable TAVI should be the new standard of care for patients with aortic stenosis who are not suitable candidates for surgery (like the patients enrolled in this study). These results cannot be extrapolated to other patients with aortic stenosis. Additional randomized trials are needed to compare TAVI with aortic-valve replacement among highrisk patients with aortic stenosis for whom surgery is a viable option and among low-risk patients with aortic stenosis. 
